Biocon Chairwoman Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Biocon Chairwoman Kiran Mazumdar Shaw has been the face of the emerging Indian biotechnology industry for decades. Under Shaw's leadership, what started in Bangalore in 1978 as a small enzyme-manufacturing unit has transformed now into a promising enterprise with partnerships with large global companies like Bristol Myers-Squibb, Pfizer and Mylan. Shaw is known for her relentless pursuit to bring out cost-effective biopharma solutions and expresses optimism about the future of biosimilars. Fresh off a deal with Pfizer for insulins, Shaw spoke at length with PharmAsia News' India Bureau about the global opportunity and regulatory challenges for biosimilars and Biocon's recent dealmaking with Mylan and Pfizer.
You may also be interested in...
Biocon Chairperson Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 2 of 2)
Biocon Chairwoman Kiran Mazumdar Shaw has been the face of the emerging Indian biotechnology industry for decades. Under Shaw's leadership, what started in Bangalore in 1978 as a small enzyme-manufacturing unit has transformed now into a promising enterprise with partnerships with large global companies like Bristol Myers-Squibb, Pfizer and Mylan. Shaw is known for her relentless pursuit to bring out cost-effective biopharma solutions and expresses optimism about the future of biosimilars. Fresh off a deal with Pfizer for insulins, Shaw spoke at length with PharmAsia News' India Bureau about the global opportunity and Biocon's recent dealmaking with Mylan and Pfizer in part one of this interview. In this second part, she discusses the regulatory challenges for biosimilars.
Biocon Chairperson Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 2 of 2)
Biocon Chairwoman Kiran Mazumdar Shaw has been the face of the emerging Indian biotechnology industry for decades. Under Shaw's leadership, what started in Bangalore in 1978 as a small enzyme-manufacturing unit has transformed now into a promising enterprise with partnerships with large global companies like Bristol Myers-Squibb, Pfizer and Mylan. Shaw is known for her relentless pursuit to bring out cost-effective biopharma solutions and expresses optimism about the future of biosimilars. Fresh off a deal with Pfizer for insulins, Shaw spoke at length with PharmAsia News' India Bureau about the global opportunity and Biocon's recent dealmaking with Mylan and Pfizer in part one of this interview. In this second part, she discusses the regulatory challenges for biosimilars.
With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market
MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro